FIELD: medicine.
SUBSTANCE: invention relates to a fused protein containing an amino acid sequence according to SEQ ID NO:16, where the fused protein is an immunomodulatory agent that increases or enhances an immune function by inhibiting ligand binding to LAIR-1, thereby reducing LAIR-1 expression, ligand binding, cross-linking, signal transmission or a combination thereof. A pharmaceutical composition containing the specified fused protein is also proposed, which is intended to stimulate an immune response to inhibit the survival of malignant cells, or to stimulate an antitumor immune response to malignant cells, or to stimulate an immune response against bacterial infections.
EFFECT: fused protein can be used to treat diseases such as ovarian cancer, lymphoma or bacterial infection.
19 cl, 25 dwg, 21 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IMMUNOCYTOKINES AND THEIR USE | 2021 |
|
RU2818371C1 |
| IL4 RECEPTOR ANTIBODIES FOR USE IN VETERINARY SCIENCE | 2019 |
|
RU2837141C2 |
| TUMOR-TARGETING AGONIST CD28 ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2837821C1 |
| ANTIBODIES TO MYOSTATIN, POLYPEPTIDES CONTAINING FC-REGION VARIANTS, AND THEIR APPLICATION METHODS | 2016 |
|
RU2789884C2 |
| FUSION PROTEIN COMPRISING IL-12 AND ANTI-FAP ANTIBODY, AND USE THEREOF | 2021 |
|
RU2831612C1 |
| TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
| ANTIBODIES TO DENGUE VIRUS, POLYPEPTIDES CONTAINING FC-REGION OPTIONS AND THEIR APPLICATION METHODS | 2017 |
|
RU2758596C2 |
| BISPECIFIC 2+1 ANTIBODIES | 2018 |
|
RU2797305C2 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES CONTAINING ANTI-FAP CLONE 212 | 2019 |
|
RU2799429C2 |
| DOG ANTIBODIES WITH MODIFIED CH-CH SEQUENCES | 2014 |
|
RU2815059C2 |
